Zacks Investment Research upgraded shares of Kura Oncology, Inc. (NASDAQ:KURA) from a hold rating to a buy rating in a report issued on Friday morning. Zacks Investment Research currently has $15.00 target price on the stock.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

KURA has been the topic of several other research reports. Cowen and Company started coverage on shares of Kura Oncology in a research note on Thursday, September 7th. They set an outperform rating on the stock. ValuEngine lowered shares of Kura Oncology from a hold rating to a sell rating in a research note on Friday, September 1st. Oppenheimer Holdings, Inc. restated an outperform rating and issued a $16.00 price target on shares of Kura Oncology in a research note on Wednesday, June 28th. Leerink Swann restated an outperform rating and issued a $18.00 price target (up previously from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. Finally, Citigroup Inc. set a $13.00 price target on shares of Kura Oncology and gave the company a buy rating in a research note on Tuesday, August 8th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $15.60.

Kura Oncology (NASDAQ KURA) traded down 2.26% during trading on Friday, hitting $12.95. The company had a trading volume of 1,610,746 shares. Kura Oncology has a 12 month low of $4.00 and a 12 month high of $13.80. The company’s 50 day moving average price is $8.37 and its 200-day moving average price is $8.90. The company’s market cap is $258.84 million.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.03. Equities analysts expect that Kura Oncology will post ($1.53) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Kura Oncology, Inc. (KURA) Upgraded to “Buy” by Zacks Investment Research” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/09/16/kura-oncology-inc-kura-upgraded-to-buy-by-zacks-investment-research.html.

Several large investors have recently made changes to their positions in KURA. Morgan Stanley increased its stake in shares of Kura Oncology by 175.5% in the first quarter. Morgan Stanley now owns 430,428 shares of the company’s stock valued at $3,788,000 after purchasing an additional 274,166 shares during the period. State Street Corp bought a new position in shares of Kura Oncology in the second quarter valued at approximately $1,394,000. Northern Trust Corp boosted its holdings in shares of Kura Oncology by 939.3% in the second quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock valued at $1,372,000 after acquiring an additional 133,293 shares in the last quarter. Alethea Capital Management LLC boosted its holdings in shares of Kura Oncology by 128.1% in the second quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock valued at $1,798,000 after acquiring an additional 108,577 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new position in shares of Kura Oncology in the first quarter valued at approximately $533,000. Institutional investors own 39.07% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.